### Supplementary Table 1: Full list of patient comorbidities at presentation

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N = 1,190 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>717 (60%)</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>451 (38%)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>393 (33%)</td>
</tr>
<tr>
<td>Coronary Artery Disease</td>
<td>153 (13%)</td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td>124 (10%)</td>
</tr>
<tr>
<td>Cerebrovascular Accident</td>
<td>100 (8.4%)</td>
</tr>
<tr>
<td>COPD or Asthma</td>
<td>202 (17%)</td>
</tr>
<tr>
<td>Other Pulmonary Condition</td>
<td>77 (6.5%)</td>
</tr>
<tr>
<td>Chronic Kidney Disease</td>
<td>106 (8.9%)</td>
</tr>
<tr>
<td>Malignancy</td>
<td>73 (6.1%)</td>
</tr>
<tr>
<td>Dementia</td>
<td>125 (11%)</td>
</tr>
<tr>
<td>HIV</td>
<td>25 (2.1%)</td>
</tr>
<tr>
<td>Hepatitis B or Hepatitis C</td>
<td>24 (2.0%)</td>
</tr>
<tr>
<td>IBD</td>
<td>12 (1.0%)</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>17 (1.4%)</td>
</tr>
<tr>
<td>Rheumatologic Disease (^1)</td>
<td>36 (3.0%)</td>
</tr>
<tr>
<td>Transplant (^2)</td>
<td>50 (4.2%)</td>
</tr>
</tbody>
</table>

\(^1\) Rheumatologic Disease = lupus, rheumatoid arthritis, or other rheumatologic disease

\(^2\) Transplant = bone marrow transplant or solid organ transplant

COPD = chronic obstructive pulmonary disease, HIV = human immunodeficiency virus, IBD = inflammatory bowel disease

### Supplementary Table 2: Baseline characteristics of patients with and without follow-up encounters at our institution

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No Follow-up Encounter</th>
<th>At Least One Follow-up Encounter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 359 (%)</td>
<td>N = 570 (%)</td>
</tr>
<tr>
<td>Number of Follow-Up Encounters(^1)</td>
<td>0.0 (0.0, 0.0)</td>
<td>3.0 (1.0, 6.0)</td>
</tr>
<tr>
<td><strong>Baseline Demographics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age(^1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age: 18-34</td>
<td>60 (46, 70)</td>
<td>60 (48, 71)</td>
</tr>
<tr>
<td>Age: 35-54</td>
<td>37 (10%)</td>
<td>58 (10%)</td>
</tr>
<tr>
<td>Age: 55-64</td>
<td>99 (28%)</td>
<td>156 (27%)</td>
</tr>
<tr>
<td>Age: 65+</td>
<td>85 (24%)</td>
<td>138 (24%)</td>
</tr>
<tr>
<td>Age: &gt;65</td>
<td>138 (38%)</td>
<td>218 (38%)</td>
</tr>
<tr>
<td>BMI</td>
<td>28 (25, 34)</td>
<td>28 (25, 33)</td>
</tr>
<tr>
<td><strong>Sex at birth</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>216 (60%)</td>
<td>326 (57%)</td>
</tr>
<tr>
<td>Female</td>
<td>143 (40%)</td>
<td>244 (43%)</td>
</tr>
<tr>
<td><strong>Race and Ethnicity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latinx Ethnicity</td>
<td>166 (46%)</td>
<td>285 (50%)</td>
</tr>
<tr>
<td>Other</td>
<td>139 (39%)</td>
<td>196 (34%)</td>
</tr>
<tr>
<td>Not Specified</td>
<td>100 (28%)</td>
<td>144 (25%)</td>
</tr>
<tr>
<td>Black</td>
<td>62 (17%)</td>
<td>118 (21%)</td>
</tr>
<tr>
<td>White</td>
<td>52 (14%)</td>
<td>104 (18%)</td>
</tr>
<tr>
<td>Asian</td>
<td>6 (1.7%)</td>
<td>8 (1.4%)</td>
</tr>
<tr>
<td><strong>Smoking Status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoker</td>
<td>294 (82%)</td>
<td>426 (75%)</td>
</tr>
<tr>
<td>Active smoker</td>
<td>19 (5.3%)</td>
<td>28 (4.9%)</td>
</tr>
<tr>
<td>Former smoker</td>
<td>44 (12%)</td>
<td>116 (20%)</td>
</tr>
<tr>
<td><strong>Medical Comorbidities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No comorbidity</td>
<td>105 (29%)</td>
<td>114 (20%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>183 (51%)</td>
<td>324 (57%)</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>119 (33%)</td>
<td>200 (35%)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>100 (28%)</td>
<td>185 (32%)</td>
</tr>
<tr>
<td>Coronary Artery Disease</td>
<td>23 (6.4%)</td>
<td>69 (12%)</td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td>26 (7.2%)</td>
<td>54 (9.5%)</td>
</tr>
<tr>
<td>Cerebrovascular Accident</td>
<td>23 (6.4%)</td>
<td>36 (6.3%)</td>
</tr>
<tr>
<td>COPD or Asthma</td>
<td>55 (15%)</td>
<td>107 (19%)</td>
</tr>
<tr>
<td>Other Pulmonary Condition</td>
<td>9 (2.5%)</td>
<td>51 (8.9%)</td>
</tr>
<tr>
<td>Chronic Kidney Disease</td>
<td>18 (5.0%)</td>
<td>46 (8.1%)</td>
</tr>
<tr>
<td>Malignancy</td>
<td>7 (1.9%)</td>
<td>39 (6.8%)</td>
</tr>
<tr>
<td>Dementia</td>
<td>30 (8.4%)</td>
<td>35 (6.2%)</td>
</tr>
<tr>
<td><strong>Disposition at Initial Hospitalization</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency Department Visit</td>
<td>62 (17%)</td>
<td>81 (14%)</td>
</tr>
<tr>
<td>Hospital Admission</td>
<td>260 (72%)</td>
<td>374 (66%)</td>
</tr>
<tr>
<td>ICU Admission</td>
<td>37 (10%)</td>
<td>115 (20%)</td>
</tr>
<tr>
<td><strong>Maximum Oxygen Requirement</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No Supplemental Oxygen</td>
<td>118 (33%)</td>
<td>193 (34%)</td>
</tr>
<tr>
<td>Nasal Cannula or Venturi Mask</td>
<td>162 (45%)</td>
<td>172 (30%)</td>
</tr>
<tr>
<td>HFNC or Non-rebreather Mask</td>
<td>44 (12%)</td>
<td>94 (16%)</td>
</tr>
<tr>
<td>Non-invasive Ventilation</td>
<td>1 (0.3%)</td>
<td>4 (0.7%)</td>
</tr>
<tr>
<td>Intubation</td>
<td>34 (9.5%)</td>
<td>107 (19%)</td>
</tr>
</tbody>
</table>

Statistics presented: Median (IQR)

BMI = body mass index; COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; HFNC = high flow nasal cannula.
**Supplementary Table 3** Characteristics of patients discharged before and after the initiation of a systematic hospital-wide COVID-19 discharge approach to provide all patients with follow up appointments

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Discharged before March 26th N = 162 (%)</th>
<th>Discharged on or after March 26th N = 767 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Follow-Up Visits(^1)</td>
<td>1.0 (0.0, 4.0)</td>
<td>1.0 (0.0, 4.0)</td>
</tr>
<tr>
<td>Any Follow-Up Visit</td>
<td>92 (57%)</td>
<td>478 (62%)</td>
</tr>
<tr>
<td>Age(^1)</td>
<td>52 (36, 65)</td>
<td>61 (50, 72)</td>
</tr>
<tr>
<td>Male</td>
<td>90 (56%)</td>
<td>452 (59%)</td>
</tr>
<tr>
<td>Female</td>
<td>72 (44%)</td>
<td>315 (41%)</td>
</tr>
<tr>
<td>Any comorbidity</td>
<td>114 (70%)</td>
<td>596 (78%)</td>
</tr>
</tbody>
</table>

\(^1\) Statistics presented: Median (IQR)
**Supplementary Table 4** Persistent symptoms\(^1\) reported for patients with follow-up encounters, arranged by history of comorbidities\(^2\)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>3 months N=488 (%)</th>
<th>6 months N=364 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any (N=394) (%)</td>
<td>No (N=94) (%)</td>
</tr>
<tr>
<td></td>
<td>Any (N=308) (%)</td>
<td>No (N=56) (%)</td>
</tr>
<tr>
<td>No Symptoms</td>
<td>154 (39%)</td>
<td>122 (40%)</td>
</tr>
<tr>
<td>Cardiopulmonary Symptoms</td>
<td>147 (37%)</td>
<td>88 (29%)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>94 (24%)</td>
<td>50 (16%)</td>
</tr>
<tr>
<td>Cough</td>
<td>62 (16%)</td>
<td>33 (11%)</td>
</tr>
<tr>
<td>Chest Pain</td>
<td>31 (7.9%)</td>
<td>23 (7.5%)</td>
</tr>
<tr>
<td>Lower Extremity Edema</td>
<td>22 (5.6%)</td>
<td>21 (6.8%)</td>
</tr>
<tr>
<td>Generalized Symptoms</td>
<td>106 (27%)</td>
<td>82 (27%)</td>
</tr>
<tr>
<td>Fever</td>
<td>36 (9.1%)</td>
<td>11 (3.6%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>39 (9.9%)</td>
<td>32 (10%)</td>
</tr>
<tr>
<td>Myalgias or Arthralgias</td>
<td>45 (11%)</td>
<td>53 (17%)</td>
</tr>
<tr>
<td>Anosmia or Aguesia</td>
<td>5 (1.3%)</td>
<td>3 (1.0%)</td>
</tr>
<tr>
<td>Neuropsychiatric Symptoms</td>
<td>85 (22%)</td>
<td>78 (25%)</td>
</tr>
<tr>
<td>Weakness</td>
<td>34 (8.6%)</td>
<td>30 (9.7%)</td>
</tr>
<tr>
<td>Altered Mentation</td>
<td>25 (6.3%)</td>
<td>19 (6.2%)</td>
</tr>
<tr>
<td>Headache</td>
<td>23 (5.8%)</td>
<td>17 (5.5%)</td>
</tr>
<tr>
<td>Depression or Anxiety</td>
<td>16 (4.1%)</td>
<td>17 (5.5%)</td>
</tr>
<tr>
<td>Gait Instability</td>
<td>6 (1.5%)</td>
<td>17 (5.5%)</td>
</tr>
<tr>
<td>Gastrointestinal or Urinary Symptoms</td>
<td>59 (15%)</td>
<td>63 (20%)</td>
</tr>
<tr>
<td>Nausea or Vomiting</td>
<td>22 (5.6%)</td>
<td>19 (6.2%)</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>20 (5.1%)</td>
<td>29 (9.4%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>14 (3.6%)</td>
<td>8 (2.6%)</td>
</tr>
<tr>
<td>Constipation</td>
<td>10 (2.5%)</td>
<td>7 (2.3%)</td>
</tr>
<tr>
<td>Urinary Symptoms</td>
<td>16 (4.1%)</td>
<td>20 (6.5%)</td>
</tr>
</tbody>
</table>

\(^1\) Persistent symptoms = symptoms that did not resolve during each three-month follow-up period

\(^2\) Comorbidity = a documented history of any of the following conditions: hypertension, diabetes mellitus, coronary artery disease, heart failure, pulmonary disease, hyperlipidemia, malignancy, chronic or end stage renal disease, cerebrovascular accident, dementia, organ transplant, hepatitis, cirrhosis, inflammatory bowel disease, HIV, or rheumatologic disease (lupus, rheumatoid arthritis, other rheumatologic disease)